Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress
December 19, 2017 12:45 ET
|
Qu Biologics
VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers
October 03, 2017 12:16 ET
|
Qu Biologics
VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement
August 02, 2017 12:29 ET
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...